NOX1 and metabolic dysfunction-associated steatohepatitis: Specifically, setanaxib has been described to replicate the beneficial effects seen in multiple NOX1/4 KO models of liver fibrosis, reducing oxidative stress, hepatocyte apoptosis, inflammation and fibrosis in different types of CLD, including NASH, bile duct ligation and CCl4 treatment [88,90].